small molecule

DIFICID

FIDAXOMICIN

Loss of exclusivityJanuary 2028latest FDA-listed patent expiry

CompanyCubist Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	DIFICID
Active ingredient	FIDAXOMICIN
Strength	200MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	May 2011
Marketing status	RX

Listed patents

Patent	Expires	Type
8859510*PED	January 2028	—
7378508*PED	January 2028	—
7863249*PED	January 2028	—
7906489*PED	September 2027	—
7863249	July 2027	substance, product
8859510	July 2027	use U-2741
7378508	July 2027	substance, product
7906489	March 2027	use U-2741

Regulatory exclusivity

Code	Expires
ODE-367	January 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Cubist Pharmaceuticals